London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Also, a 10% hospitalisation rate for Monkeypox, very dangerous disease for both Children and Pregnant women. There's already talk of this becoming Endemic.
Hi neilrich i think your counting the rising amount of variants and mutations running for pm
Truth is, novacyt are never gonna make anything from COVID anymore . This should be 240p based on NAV and 350p when they win Court case. Facts
Let's not forget that the Pandemic is still raging, it ain't going away and there's still a requirement for testing, whether the Government likes it or not. On top of this we have Monkeypox, which some experts are already suggesting should now be declared a Pandemic.
“A new study also suggests that the virus might be mutating 12 times faster than expected, and could lead to 60,000 new cases per day in the U.K. alone by the end of 2022” this is for Monkeypox, potentially that's a lot of additional testing globally, on top of COVID.
Maybe Monty but we can only go on what the chaps at the round table are telling us, and that's trending down after down after down. Hopefully FY23 will be our first year of growth since FY20. 12 months ago I would have said no problem achieving that goal but with only £0.5m of non covid sales in the last 3 months it is now going to be a considerable challenge.
We are asset and cash positive that practically matches our market value. We are likely to come out of the current litigation cash neutral or potentially with a win. We have to be proven to have breached a contract with substantial evidence. Did the sloppy lazy DHS produce clear binding performance contracts? Did our products not perform to those contracts with irrefutable evidence (I doubt it very much). Why are there Director purchases if it’s all down and down. I note we preserved our cash really well in the past year, our margins are very high when we do get jobs. Yes we need Sales to be more proactive, but maybe they are and we will be getting positive updates soon. There is a lot more to like than not too at the current SP. (All IMHO)
Agree DRB, - from the last RNS:
"The Company continues to invest in R&D and Commercial resources, which represents £10.0m of projected opex spend in 2022..."
Ncyt have already told us that they expect £25m revenue and £4.5m EBITDA loss so not following your numbers. Also, the £10m of R&D spend is opex not capex.
Katherine H. Technical support specialist. Is one of them
Sorry i can't... Have stopped following them after finding 'mnew job or telling open for opportunities So dunno the names anymore. No "Big" ppl, technicians, production specilists, such things if i remember good.
To your second question, no, no such group im aware of. I wrote a Big mail to the BoD alone on my side, which will as usual stay unanswered.
baby - the buck stops with the head honcho. If someone else is writing the RNS - then salad man should sack him!
my problem is that either there is no coherent strategy or if there are then they - or rather he - is not communicating it to the market...And quite frankly that is down to the salad man
I was looking on LinkedIn a few days ago to see if people were leaving, can you give any names Larry. Also interested if you know of any shareholder activist groups forming to push for a meeting for a full and frank discussion
Swag, I started complaining when I saw the rubbish new website, then came a rubbish LFT launch, then a non-agm, then we had the horrid trading update. Is DA meant to be doing all that stuff himself? NCYT has a global marketing mgr, a digital brand mgr, that website and LFT launch is their responsibility, the non-agm Mandy's responsibility, dire sales update, there's several people responsible before DA. DA's 100 day review and strategy, I think it's OK, but it's not really been implemented, just repeated.
For the record I don't think he's up to the role, but that's because of the scale of the problem that is emerging. Novacyt has been through upheaval and the current leadership is weak, the wrong people have been hired in the past 2 years to drive the business. But starting again with a new CEO won't guarantee a solution but will prolong the pain, better to work with what you have until waters are less choppy.
Tests cost money, lets give WHO novacyt shares instead, much cheaper. Actually increase the price of every product novacyt sell by £2.30 and include a free share with every purchase, instantly doubling todays share price. The rising SP will attract support, pushing it further beyond £2.30. This will drive sales as customers are getting a discounted share with every purchase. The increased sales will attract more support for the SP and in turn even more customers for an increasingly discounted share with every purchase. Regular share issuances will be needed off course to keep up with demand. Simples.
you don't account for capital expenditures in gross margin so gross margins are fairly meaningless in pharma and tech industries and really meaningless for companies like NCYT as it's basically a R&D company and R&D is a capital expenditure. Big pharma will invest about 25% of revenue in R&D, for NCYT it's probably hitting 50%. Hence why for 2022 NCYT will make ~70% gross margin on sales of ~£7mm and lose ~£10mm. Who says accounting ain't fun.
Me too Easy C.
Larry I was being flippant about one new employee it doesn't make or break anything.
Frustrating as it is, things seem to be happening in the background. We know TATA MD are using our equipment. They might be wanting to partner up with us. Why are they not being mentioned by name. I am willing to wait this out and hope DA is actually doing his job. But will not vote for pay increases.
Shes been here since april. Its been a few month already. So wouldnt Say "New".
Re cost base, already Saw a few staff "looking for New opportunitys" this week. 4-5-6 dunno anymore.
From RNS : "the Company is taking steps to further rationalise its cost base, targeting an additional reduction in operating costs of £2.4m this year and a one-off cash restructuring charge of circa £0.8m".
I would think they know what they have to do...
As Kaeren said, unsure it’s a good idea. We should be cutting the cost base as much as possible currently, not shelling out the best part of £100k to bring In little revenue. But who are we to judge, DA is at the wheel.
I don't know that it is good to be expanding cost base at the moment. Unless they know something they aren't telling us.
Seventeen new PCR assays sandwiched between negative news , FIFTEEN of them non covid . What 8 new STD assays? Which distributor ? Do they have sole distribution rights ?
What NGO have you signed a contract with to supply tests to support detection
of Arboviruses such as dengue , Zika and Chikungunya. How long is the contract for ?
What global health provider have you signed a three year agreement with to provide instruments and reagents ?
Why no mention of the new LFTs, just woffle about a new reader , which unless I'm mistaken can be bought off the shelf.
So many bits of info , none delivered in such a way that holders can comprehend potential fiscal worth. Don't accept all the above is NDA , the dispute yes , but every other diagnostic company sings from the hilltops about new releases / contracts. Is the major health provider Tata ? I havent got a clue. First on my list for sacking is whoever scripts these RNS 's they are absolutely disastrous.
Off to the airport , might suggest guests hire a car as cheaper then driving to Dublin and back !
https://www.linkedin.com/in/berna-gimenez-kappeler/
Good to see that we are expanding the sales team into LATAM.
Apologies -
'Note 1 - David Allmond stated Novacyt not going head to head with big guys.'
I'm pretty sure they will return 90% of the cash to shareholders after the dhsc case. I mean , ncyt do not need that kind of money
Hi Poidster -
..."it was almost cover to cover advertisements for point of care testing equipment, all the main players (Abbott, Roche, Siemens etc) were heavily advertised."...
IT-IS instruments have been marketed as ideal for use in a point of care environment.
http://novacyt.com/wp-content/uploads/2022/04/Investor-Presentation-28.04.2022-Website.pdf -
Slide titled - "Novacyt has a differentiated proposition in the decentralised market segment"
Note 1 - GM stated Novacyt not going head to head with big guys.
Novacyt is present in the central panel labelled 'Decentralised', but not present in the other two panels that contain 'the big guns'.
Note 2 - Note the footer text of this slide
'Novacyt has global commercial reach through direct presence and a comprehensive distributor network'.
If we report Group Revenue as poor as this again, like we saw in Thursday's RNS, - these distributors will begin distributing for others, - probably competitors. Why stick around?
I assume distributors prices are dictated by Novacyt head office, so why employ people to sell goods with a large price ticket.
Note 3 Slide titled "Evolving Novacyt beyond the pandemic" in the appendix.
Contains the text 'Ambition >£100m of revenue by ~2026'.
James McCarthy said in the 'investor meet' meeting:
'If you look further ahead we are calling on a figure of £100 million of revenue in 5 years and just to be clear this does not include any acquisition activity.
This is organic growth, acquisitions of course may accelerate that target, may make it bigger, - acquisitions are difficult to predict, but the £100 million is an organic number.'
++++
For me, product pricing would be the place to review where things are going wrong, we don't lack sales staff.
The best sales staff have trouble selling when prices are too high.
The last RNS is a really poor 'starter for ten' for £100 million revenue by 2026.
Instead of incinerating their written off tests they should defo donate. 100% agree but we know they won't as they are too arrogant and proud.
Ncyt seems to be the only UK listed COVID stock trading below its NAV. Lol. I mean it's just bizarre, with a revised NAV of £170m near 240p. AVCT have £26m cash , £41m in net assets yet trade at £260m market cap . MHC and ODX trade at double . I mean a lot of it has to to do with the way the RNSs have been worded, but my word what a ****show from DA. Lol.